Hunan Jingfeng Pharmaceutical Co

Hunan Jingfeng Pharmaceutical Co Debt

The Debt of Hunan Jingfeng Pharmaceutical Co (000908.SZ) as of Oct 22, 2026 is 198.38 M CNY. In the previous year, Debt was 593.88 M CNY — a change of -66.60% (lower).

Debt

198.38 MCNY

YoY

-66.60%

Last updated:

In 2024, Hunan Jingfeng Pharmaceutical Co's total debt was 198.38 M CNY, a -66.60% change from the 593.88 M CNY total debt recorded in the previous year.

The Hunan Jingfeng Pharmaceutical Co Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2017
1.80 B CNY
Jan 1, 2018
1.77 B CNY
Jan 1, 2019
1.70 B CNY
Jan 1, 2020
1.42 B CNY
Jan 1, 2021
873.52 M CNY
Jan 1, 2022
598.81 M CNY
Jan 1, 2023
593.88 M CNY
Jan 1, 2024
198.38 M CNY
The Hunan Jingfeng Pharmaceutical Co Debt history
YEARDebtYoY
198.38 MCNY-66.60%
593.88 MCNY-0.82%
598.81 MCNY-31.45%
873.52 MCNY-38.62%
1.42 BCNY-16.07%
1.70 BCNY-4.19%
1.77 BCNY-1.91%
1.80 BCNY-8.85%
1.98 BCNY+192.25%
677.25 MCNY+26.35%
536.00 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Hunan Jingfeng Pharmaceutical Co Stock analysis

What does Hunan Jingfeng Pharmaceutical Co do? Hunan Jingfeng Pharmaceutical Co., Ltd. generates revenue through the research, development, manufacture, and sale of chemical and biological drugs. Its main product categories include cardio and cerebrovascular drugs, antihypertensive and hypolipidemic drugs, orthopedic drugs, anti-tumor products, endocrine drugs, digestive system drugs, antiviral drugs, and anti-infective drugs. The company distributes these products domestically and also engages in commodity import and export trading, business management and consulting, and medical technology consulting services. Sales are primarily directed at the domestic market with no mention of international distribution channels. The firm's revenue streams are derived from pharmaceutical sales, particularly in cardiovascular, oncology, and infectious disease treatments, alongside ancillary services such as medical technology consulting. The domestic market remains the sole focus for product distribution, with no indication of export-oriented sales. The company's operations are centered on drug manufacturing and related consulting services, targeting healthcare providers and domestic consumers through established distribution networks. Hunan Jingfeng Pharmaceutical's business model emphasizes product diversity across multiple therapeutic areas, including cardiovascular, oncology, and infectious diseases. The company's revenue is driven by both direct pharmaceutical sales and ancillary consulting services, with all activities confined to the domestic market. The absence of international operations or export-focused strategies is consistent with the business description provided. Hunan Jingfeng Pharmaceutical Co is one of the most popular companies on Eulerpool.

Debt Details

Understanding Hunan Jingfeng Pharmaceutical Co's Debt Structure

Hunan Jingfeng Pharmaceutical Co's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Hunan Jingfeng Pharmaceutical Co's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Hunan Jingfeng Pharmaceutical Co’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Hunan Jingfeng Pharmaceutical Co’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Hunan Jingfeng Pharmaceutical Co stock

Debt of Hunan Jingfeng Pharmaceutical Co is 198.38 M CNY in 2024.

Debt of Hunan Jingfeng Pharmaceutical Co changed from 593.88 M CNY to 198.38 M CNY, representing a -66.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Hunan Jingfeng Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

Debt's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Hunan Jingfeng Pharmaceutical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Hunan Jingfeng Pharmaceutical Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Hunan Jingfeng Pharmaceutical Co